Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
Status:
Terminated
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to identify and/or validate biomarkers and imaging markers to
predict and monitor the activity of a new class of therapeutic agents called antiangiogenics
for the treatment of metastatic renal cell carcinoma (mRCC). Suntinib, approved for this
indication, will be administred before and after nephrectomy and biomarkers sampling and
imaging will be operated to monitor the activity and identify prognostic factors in mRCC.